257 related articles for article (PubMed ID: 32295876)
1. The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137
Foda BM; Ciecko AE; Serreze DV; Ridgway WM; Geurts AM; Chen YG
J Immunol; 2020 Jun; 204(11):2887-2899. PubMed ID: 32295876
[TBL] [Abstract][Full Text] [Related]
2. CD137 Plays Both Pathogenic and Protective Roles in Type 1 Diabetes Development in NOD Mice.
Forsberg MH; Ciecko AE; Bednar KJ; Itoh A; Kachapati K; Ridgway WM; Chen YG
J Immunol; 2017 May; 198(10):3857-3868. PubMed ID: 28363905
[TBL] [Abstract][Full Text] [Related]
3. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice.
Kachapati K; Bednar KJ; Adams DE; Wu Y; Mittler RS; Jordan MB; Hinerman JM; Herr AB; Ridgway WM
J Autoimmun; 2013 Dec; 47():94-103. PubMed ID: 24145149
[TBL] [Abstract][Full Text] [Related]
4. The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.
Kachapati K; Adams DE; Wu Y; Steward CA; Rainbow DB; Wicker LS; Mittler RS; Ridgway WM
J Immunol; 2012 Nov; 189(10):5001-15. PubMed ID: 23066155
[TBL] [Abstract][Full Text] [Related]
5. CD137 ligand reverse signaling skews hematopoiesis towards myelopoiesis during aging.
Tang Q; Koh LK; Jiang D; Schwarz H
Aging (Albany NY); 2013 Sep; 5(9):643-52. PubMed ID: 23945137
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.
Luu K; Patwardhan MV; Zeng Q; Wickström SL; Lundqvist A; Schwarz H
Cells; 2021 Feb; 10(2):. PubMed ID: 33572150
[TBL] [Abstract][Full Text] [Related]
7. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes.
Rojas M; Heuer LS; Zhang W; Chen YG; Ridgway WM
Front Immunol; 2022; 13():918837. PubMed ID: 35935980
[TBL] [Abstract][Full Text] [Related]
8. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice.
Sgouroudis E; Albanese A; Piccirillo CA
J Immunol; 2008 Nov; 181(9):6283-92. PubMed ID: 18941219
[TBL] [Abstract][Full Text] [Related]
9. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.
Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M
J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316
[TBL] [Abstract][Full Text] [Related]
10. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model.
Holohan DR; Van Gool F; Bluestone JA
PLoS One; 2019; 14(10):e0217728. PubMed ID: 31647813
[TBL] [Abstract][Full Text] [Related]
11. Gene targeting in NOD mouse embryos using zinc-finger nucleases.
Chen YG; Forsberg MH; Khaja S; Ciecko AE; Hessner MJ; Geurts AM
Diabetes; 2014 Jan; 63(1):68-74. PubMed ID: 23974926
[TBL] [Abstract][Full Text] [Related]
12. CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.
Wong HY; Schwarz H
J Autoimmun; 2020 Aug; 112():102499. PubMed ID: 32505443
[TBL] [Abstract][Full Text] [Related]
13. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
14. Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.
Martínez Gómez JM; Koh VH; Yan B; Lin W; Ang ML; Rahim SZ; Pethe K; Schwarz H; Alonso S
Immunobiology; 2014 Jan; 219(1):78-86. PubMed ID: 24091276
[TBL] [Abstract][Full Text] [Related]
15. Transient Depletion of Foxp3
Watts D; Janßen M; Jaykar M; Palmucci F; Weigelt M; Petzold C; Hommel A; Sparwasser T; Bonifacio E; Kretschmer K
Front Immunol; 2021; 12():720133. PubMed ID: 34447385
[TBL] [Abstract][Full Text] [Related]
16. CD137-CD137L interaction regulates atherosclerosis via cyclophilin A in apolipoprotein E-deficient mice.
Li Y; Yan J; Wu C; Wang Z; Yuan W; Wang D
PLoS One; 2014; 9(2):e88563. PubMed ID: 24520398
[TBL] [Abstract][Full Text] [Related]
17. Allergen-specific immunotherapy enhances CD8
Tsai YG; Yang KD; Wen YS; Hung CH; Chien JW; Lin CY
Pediatr Allergy Immunol; 2019 Aug; 30(5):531-539. PubMed ID: 30968455
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes.
Stocks BT; Wilson CS; Marshall AF; Hoopes EM; Moore DJ
J Immunol; 2019 Jul; 203(1):158-166. PubMed ID: 31127035
[TBL] [Abstract][Full Text] [Related]
19. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells.
Ly D; Mi QS; Hussain S; Delovitch TL
J Immunol; 2006 Sep; 177(6):3695-704. PubMed ID: 16951329
[TBL] [Abstract][Full Text] [Related]
20. CD137-CD137L interaction modulates neointima formation and the phenotype transformation of vascular smooth muscle cells via NFATc1 signaling.
Zhong W; Li B; Yang P; Chen R; Wang C; Wang Z; Shao C; Yuan W; Yan J
Mol Cell Biochem; 2018 Feb; 439(1-2):65-74. PubMed ID: 28770466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
